Compile Data Set for Download or QSAR
Report error Found 22 Enz. Inhib. hit(s) with all data for entry = 6477
TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Aska Pharmaceutical

US Patent
LigandPNGBDBM131008(US8829000, 70)
Affinity DataIC50: 1.20nMT: 2°CAssay Description:To 150 uL of buffer B (70 mmol/L Tris-HCl, pH7.5, 16.7 mmol/L MgCl2, 33.3 nmol/L [3H]-cGMP) solution containing [3H]-cGMP (specific activity=244.2 GB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2015
Entry Details
Go to US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Aska Pharmaceutical

US Patent
LigandPNGBDBM131013(US8829000, 185)
Affinity DataIC50: 2nMT: 2°CAssay Description:To 150 uL of buffer B (70 mmol/L Tris-HCl, pH7.5, 16.7 mmol/L MgCl2, 33.3 nmol/L [3H]-cGMP) solution containing [3H]-cGMP (specific activity=244.2 GB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2015
Entry Details
Go to US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Aska Pharmaceutical

US Patent
LigandPNGBDBM131014(US8829000, 187)
Affinity DataIC50: 2nMT: 2°CAssay Description:To 150 uL of buffer B (70 mmol/L Tris-HCl, pH7.5, 16.7 mmol/L MgCl2, 33.3 nmol/L [3H]-cGMP) solution containing [3H]-cGMP (specific activity=244.2 GB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2015
Entry Details
Go to US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Aska Pharmaceutical

US Patent
LigandPNGBDBM131010(US8829000, 85)
Affinity DataIC50: 3nMT: 2°CAssay Description:To 150 uL of buffer B (70 mmol/L Tris-HCl, pH7.5, 16.7 mmol/L MgCl2, 33.3 nmol/L [3H]-cGMP) solution containing [3H]-cGMP (specific activity=244.2 GB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2015
Entry Details
Go to US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Aska Pharmaceutical

US Patent
LigandPNGBDBM131012(US8829000, 180)
Affinity DataIC50: 3nMT: 2°CAssay Description:To 150 uL of buffer B (70 mmol/L Tris-HCl, pH7.5, 16.7 mmol/L MgCl2, 33.3 nmol/L [3H]-cGMP) solution containing [3H]-cGMP (specific activity=244.2 GB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2015
Entry Details
Go to US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Aska Pharmaceutical

US Patent
LigandPNGBDBM131009(US8829000, 82)
Affinity DataIC50: 3.40nMT: 2°CAssay Description:To 150 uL of buffer B (70 mmol/L Tris-HCl, pH7.5, 16.7 mmol/L MgCl2, 33.3 nmol/L [3H]-cGMP) solution containing [3H]-cGMP (specific activity=244.2 GB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2015
Entry Details
Go to US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Aska Pharmaceutical

US Patent
LigandPNGBDBM131011(US8829000, 86)
Affinity DataIC50: 8nMT: 2°CAssay Description:To 150 uL of buffer B (70 mmol/L Tris-HCl, pH7.5, 16.7 mmol/L MgCl2, 33.3 nmol/L [3H]-cGMP) solution containing [3H]-cGMP (specific activity=244.2 GB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2015
Entry Details
Go to US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Aska Pharmaceutical

US Patent
LigandPNGBDBM131015(US8829000, 189)
Affinity DataIC50: 8nMT: 2°CAssay Description:To 150 uL of buffer B (70 mmol/L Tris-HCl, pH7.5, 16.7 mmol/L MgCl2, 33.3 nmol/L [3H]-cGMP) solution containing [3H]-cGMP (specific activity=244.2 GB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2015
Entry Details
Go to US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Aska Pharmaceutical

US Patent
LigandPNGBDBM131016(US8829000, Referential Example 1)
Affinity DataIC50: 8nMT: 2°CAssay Description:To 150 uL of buffer B (70 mmol/L Tris-HCl, pH7.5, 16.7 mmol/L MgCl2, 33.3 nmol/L [3H]-cGMP) solution containing [3H]-cGMP (specific activity=244.2 GB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2015
Entry Details
Go to US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Aska Pharmaceutical

US Patent
LigandPNGBDBM131006(US8829000, 6)
Affinity DataIC50: 10nMT: 2°CAssay Description:To 150 uL of buffer B (70 mmol/L Tris-HCl, pH7.5, 16.7 mmol/L MgCl2, 33.3 nmol/L [3H]-cGMP) solution containing [3H]-cGMP (specific activity=244.2 GB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2015
Entry Details
Go to US Patent

TargetHigh affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A(Human)
Aska Pharmaceutical

US Patent
LigandPNGBDBM131007(US8829000, 9)
Affinity DataIC50: 42nMT: 2°CAssay Description:To 150 uL of buffer B (70 mmol/L Tris-HCl, pH7.5, 16.7 mmol/L MgCl2, 33.3 nmol/L [3H]-cGMP) solution containing [3H]-cGMP (specific activity=244.2 GB...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2015
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Aska Pharmaceutical

US Patent
LigandPNGBDBM131006(US8829000, 6)
Affinity DataIC50: 1.26E+3nMT: 2°CAssay Description:By a method similar to the measurement of PDE9-inhibiting activity, PDE5-inhibiting activity of each of the test compounds was measured, percent inhi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2015
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Aska Pharmaceutical

US Patent
LigandPNGBDBM131016(US8829000, Referential Example 1)
Affinity DataIC50: 1.34E+3nMT: 2°CAssay Description:By a method similar to the measurement of PDE9-inhibiting activity, PDE5-inhibiting activity of each of the test compounds was measured, percent inhi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2015
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Aska Pharmaceutical

US Patent
LigandPNGBDBM131012(US8829000, 180)
Affinity DataIC50: 2.81E+3nMT: 2°CAssay Description:By a method similar to the measurement of PDE9-inhibiting activity, PDE5-inhibiting activity of each of the test compounds was measured, percent inhi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2015
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Aska Pharmaceutical

US Patent
LigandPNGBDBM131015(US8829000, 189)
Affinity DataIC50: 4.56E+3nMT: 2°CAssay Description:By a method similar to the measurement of PDE9-inhibiting activity, PDE5-inhibiting activity of each of the test compounds was measured, percent inhi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2015
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Aska Pharmaceutical

US Patent
LigandPNGBDBM131014(US8829000, 187)
Affinity DataIC50: 6.37E+3nMT: 2°CAssay Description:By a method similar to the measurement of PDE9-inhibiting activity, PDE5-inhibiting activity of each of the test compounds was measured, percent inhi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2015
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Aska Pharmaceutical

US Patent
LigandPNGBDBM131011(US8829000, 86)
Affinity DataIC50: 7.54E+3nMT: 2°CAssay Description:By a method similar to the measurement of PDE9-inhibiting activity, PDE5-inhibiting activity of each of the test compounds was measured, percent inhi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2015
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Aska Pharmaceutical

US Patent
LigandPNGBDBM131007(US8829000, 9)
Affinity DataIC50: 1.00E+4nMT: 2°CAssay Description:By a method similar to the measurement of PDE9-inhibiting activity, PDE5-inhibiting activity of each of the test compounds was measured, percent inhi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2015
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Aska Pharmaceutical

US Patent
LigandPNGBDBM131008(US8829000, 70)
Affinity DataIC50: 1.00E+4nMT: 2°CAssay Description:By a method similar to the measurement of PDE9-inhibiting activity, PDE5-inhibiting activity of each of the test compounds was measured, percent inhi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2015
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Aska Pharmaceutical

US Patent
LigandPNGBDBM131009(US8829000, 82)
Affinity DataIC50: 1.00E+4nMT: 2°CAssay Description:By a method similar to the measurement of PDE9-inhibiting activity, PDE5-inhibiting activity of each of the test compounds was measured, percent inhi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2015
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Aska Pharmaceutical

US Patent
LigandPNGBDBM131010(US8829000, 85)
Affinity DataIC50: 1.00E+4nMT: 2°CAssay Description:By a method similar to the measurement of PDE9-inhibiting activity, PDE5-inhibiting activity of each of the test compounds was measured, percent inhi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2015
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Aska Pharmaceutical

US Patent
LigandPNGBDBM131013(US8829000, 185)
Affinity DataIC50: 1.00E+4nMT: 2°CAssay Description:By a method similar to the measurement of PDE9-inhibiting activity, PDE5-inhibiting activity of each of the test compounds was measured, percent inhi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/16/2015
Entry Details
Go to US Patent